DNA Delivery Systems for Gene Therapies
Dr. Vivienne Raper has written an excellent FutureLab/Biocompare editorial comparing the various...
Newsroom
FDA lays out plan to boost gene therapy approvals
The FDA has approved 12 gene therapies so far, and the agency's top drug regulator wants to see the...
SIRION Receives ISO 9001:2015 Certification
Munich, Germany, February 23, 2022 – SIRION Biotech GmbH is proud to announce our achievement of...
PerkinElmer’s SIRION Biotech Teams with Centre for Genomic Regulation to Develop New Generation AAV Vectors for Type 1 and Type 2 Diabetes Gene Therapy
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
...
SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, Research and Innovation
Munich, October 8, 2021: The French Ministry of Higher Education, Research and Innovation have...
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
Solutions to complement Company’s growing position in cell and gene therapy research and development
Bavarian Technology Trio Racing Forward
Bavarian trio unite for French round-the-world sailing race: NanoTemper and SIRION Biotech support...
Subscribe Here!
Contact Us
Whether you seek help customizing a vector for academic use or support for your industrial R&D, we will assist you from square one to discuss and plan your project in detail.
News
SIRION Biotech is now part of the Revvity portfolio!
SIRION Biotech licences its LentiBOOST® transduction technology to Cellectis
Meet us
AAV Webinar
On Demand
CAR-TCR Summit
August 29 - September 1, Boston
Meet Benjamin Eberhardt, LentiBOOST Product Manager! Eberhardt@sirion-biotech.com
Japan Society of Cell and Gene Therapy
September 11 - September 13, Osaka
BIOJapan
October 11 - October 13, Yokohama